Home Parenteral Nutrition
Conditions
Keywords
Home parenteral nutrition, Liver injury, Intravenous Lipid Emulsions, Catheter-related infections, Safety
Brief summary
Total Parenteral Nutrition (TPN) is a way of feeding a person intravenously, and is required when the gastrointestinal tract is not able to function properly. TPN contains carbohydrates, protein, and fat and lipids. It also contains minerals and vitamins. The lipid that is currently used at the University Health Network home TPN program is Intralipid20%, which is based on Soybean oil, contains polyunsaturated fats and is a good source of energy and essential fatty acids, including omega 3 and 6 fatty acids, which needed by the body. However, long term use on Intralipid20% has been shown to have negative effects on antioxidant status, inflammation, liver, and the immune system. SMOFlipid20% is a lipid emulsion that has been designed to maximize the ratio of omega 3 to omega 6 fatty acids, in an effort to avoid potentially harmful effects associated with Intralipid20%. In previous studies, it has been shown that SMOFlipid20% is safe and has positive benefits on the liver enzymes. There are no studies so far which follow patient who is on SMOFlipid20% long term. The investigators hope to show that with long term use of SMOFlipid20% is better for liver function compared to Intralipid20%.
Detailed description
A prospective double-blind, crossover, randomized clinical trial of 13 months duration per participant to compare between 2 commercially available lipid emulsion, Intralipid vs SMOF, in patient receiving home parenteral nutrition (HPN). All subjects are stable HPN patients who receive Intralipid as lipid emulsion in their solutions. The subjects will be randomized to two groups. One group will receive Intralipid for 6 months, followed by 28 days of wash-out period, and then will receive SMOF for 6 months. Another groups will receive SMOF in first 6 months, followed by 28 days of wash-out period, then will receive Intralipid for 6 months. During wash-out period for both groups, the patients will receive Intralipid as standard lipid emulsion. Each patient will have 4 clinic visits at Toronto General Hospital for clinical interview, nutritional measurements, routine blood tests, and special blood tests at baseline then at 6, 7, 13 months. Also, the patients will be asked to have routine blood tests after month 3 and month 9. The patients will fill the food record which will be collected later after completion of each period, month 6 and 13 of the study. The investigators will be calling patients during both periods to check compliance and update on their condition including the adverse events.
Interventions
DRUGSMOFlipid20%
Sponsors
Johane Allard
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed and dated informed consent form (ICF) to participate before any study related procedures are performed * Adult over the age of 18 * Both males and females * Clinically stable for at least 4 weeks with no acute medical co-morbidities * Patients on a stable Intralipid HPN regimen for 6 months and expected to require long-term PN for at least 13 more months
Exclusion criteria
Subjects not already on Intralipid PN Inability to give informed consent Alcohol or drug abuse Pregnant and lactating women Clinical instability such as the following: * Acute pulmonary edema * Decompensated heart failure * Decompensated chronic liver disease * Severe post-traumatic conditions * Uncontrolled diabetes mellitus * Acute myocardial infarction * Acute stroke * Acute thromboembolism * Metabolic acidosis * Sepsis * Hypotonic dehydration * Coagulopathy with prolonged aPTT or INR Elevated triglyceride level: more than 4.5 mmol/L Active malignancy with life expectancy less than one year Subjects who are hypersensitive or allergic to the product ingredients of SMOF or Intralipid, including soybean oil, peanuts, fish oil, and egg as well as allergy to peanuts.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in alanine transaminase (ALT) | baseline 1, 6 months, baseline 2 (7 mo), 13 months |
Secondary
| Measure | Time frame |
|---|---|
| changes in liver function tests (total and conjugated bilirubin, ALP, AST, GGT) | baseline 1, 6 months, baseline 2 (7 mo), 13 months |
| rate of infections (central line and other) per 1000 catheter days | baseline 1, 6 months, baseline 2 (7 mo), 13 months |
| antibiotic days for acute infections | baseline 1, 6 months, baseline 2 (7 mo), 13 months |
| number of hospitalizations for the past 6 months | baseline 1, 6 months, 13 months |
| number of catheter changes for the past 6 months | baseline 1, 6 months, 13 months |
Countries
Canada
Outcome results
None listed